Overall, the suppression of LINC00511 curtailed tumor growth and altered the expression of related biomarkers, providing crucial insights for understanding the molecular mechanism of CCA and advancing the development of new therapeutic strategies. This evidence concerns the gene LINC00511 and cholangiocarcinoma.